Illumina Warns of 'Temporary' Slowdown in GWAS Growth Rate, Posts 36 Percent Rise in Q1 Sales

While Illumina officials said the company's sequencing and microarray product lines experienced "significant growth" in the quarter, they also cautioned that the growth rate for whole-genome BeadChips will soon slow as customers wait for the company to translate content generated by sequencing efforts like the 1000 Genomes Project into new products.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.